The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

After he stopped responding to several different therapies aimed at prolonging his life, doctors advised him to try a drug ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

A case of a deadly new mpox strain has been detected in the UK for the first time ... Monkeypox is an infectious disease caused by the monkeypox virus. It can cause a painful rash, enlarged ...

Myeloma UK estimates around 24,000 people are affected by the disease in the UK, with an estimated 5,900 new diagnoses each year. Caroline Donoghue, senior policy officer at the charity ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Meanwhile, Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of ...

Yet more growth momentum is on the cards because it was recently cleared to treat a common lung disease. Sanofi earlier this week announced it was in exclusive talks to sell a controlling stake in ...